PMID- 25987653
OWN - NLM
STAT- MEDLINE
DCOM- 20150727
LR  - 20150519
IS  - 1472-4146 (Electronic)
IS  - 0021-9746 (Linking)
VI  - 68
IP  - 6
DP  - 2015 Jun
TI  - Gene of the month: MET.
PG  - 405-9
LID - 10.1136/jclinpath-2015-203050 [doi]
AB  - The MET receptor tyrosine kinase and its ligand hepatocyte growth factor/scatter 
      factor (HGF/SF) are potential therapeutic targets in many human malignancies, 
      making this pathway an important focus of molecular and cancer research. MET 
      mutations have been detected in various tumours. In addition, many tumour types 
      demonstrate MET and HGF/SF overexpression and amplification. The MET signal 
      transduction cascade is complex, and manifests in a broad spectrum of mitogenic 
      and morphogenic functions, affecting cell proliferation, migration, 
      differentiation, morphology and survival. Cancer cells commandeer the 
      physiological functions of this signalling axis to facilitate invasion and 
      metastasis. Significant progress has been made in the development of agents that 
      inhibit MET-HGF/SF signalling. In this article, we outline the key features of 
      the MET gene, its protein product and the ligand HGF/SF, to provide an overview 
      of this important signalling pathway and offer a summary of the relevant 
      pathological and clinical directions of research.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Skead, Garret
AU  - Skead G
AD  - Division of Anatomical Pathology, University of Cape Town and National Health 
      Laboratory Service, Groote Schuur hospital, Cape Town, South Africa.
FAU - Govender, Dhirendra
AU  - Govender D
AD  - Division of Anatomical Pathology, University of Cape Town and National Health 
      Laboratory Service, Groote Schuur hospital, Cape Town, South Africa.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150422
PL  - England
TA  - J Clin Pathol
JT  - Journal of clinical pathology
JID - 0376601
RN  - 0 (Protein Kinase Inhibitors)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - EC 2.7.10.1 (MET protein, human)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - IM
EIN - J Clin Pathol. 2015 Jul;68(7):e2. PMID: 26093021
MH  - Germ-Line Mutation/*genetics
MH  - Hepatocyte Growth Factor/genetics
MH  - Humans
MH  - Mutation, Missense/*genetics
MH  - Neoplasms/drug therapy/*genetics
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Proto-Oncogene Proteins c-met/antagonists & inhibitors/*genetics
MH  - Signal Transduction/genetics
OTO - NOTNLM
OT  - CANCER
OT  - GENE AMPLIFICATION
OT  - GENETICS
OT  - ONCOGENES
EDAT- 2015/05/20 06:00
MHDA- 2015/07/28 06:00
CRDT- 2015/05/20 06:00
PHST- 2015/04/02 00:00 [accepted]
PHST- 2015/05/20 06:00 [entrez]
PHST- 2015/05/20 06:00 [pubmed]
PHST- 2015/07/28 06:00 [medline]
AID - jclinpath-2015-203050 [pii]
AID - 10.1136/jclinpath-2015-203050 [doi]
PST - ppublish
SO  - J Clin Pathol. 2015 Jun;68(6):405-9. doi: 10.1136/jclinpath-2015-203050. Epub 
      2015 Apr 22.